Zentalis Pharmaceuticals, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.zentalis.com

Market Cap $86.01M
PE -0
Debt -
Cash $44.56M
EV -
FCF -$151.70M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$224.19M
EBIT	-$221.50M
ROE	-76%
ROA	-58%
FCF	-$151.70M
Equity	$295.38M
Growth Stability	1
PE	-0.38
PB	0.29
P/FCF	-0.57
P/S	3.2
Price/Cash	0.52
Op. Margins	-824%
Sales Growth YoY	-100%
Sales Growth QoQ	-100%
Sales CAGR	-0%
Equity CAGR	28%
Earnings Growth YoY	-581%

Earnings Growth QoQ	2%
Sales CAGR 5Y	-0%
Equity CAGR 5Y	6%
Earnings CAGR 3Y	-2%
Sales CAGR 3Y	-2%
Equity CAGR 3Y	-12%
Market Cap	$86.01M
Revenue	$26.87M
Assets	$384.02M
Cash	$44.56M
Shares Outstanding	71.68M
Working Capital	293.45M
Current Ratio	6.94
Shares Growth 3y	16%
Equity Growth QoQ	-12%
Equity Growth YoY	-36%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

SEC Filings

Direct access to Zentalis Pharmaceuticals, Inc. (ZNTL) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Zentalis Pharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Zentalis Pharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Zentalis Pharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Zentalis Pharmaceuticals, Inc..

Years

Calculation mode

= -$1.5B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$152M	-$152M	-$152M	-$152M	-$152M	-$152M	-$152M	-$152M	-$152M	-$152M	-$152M	-$1.5B
DCF		-$138M	-$125M	-$114M	-$104M	-$94M	-$86M	-$78M	-$71M	-$64M	-$58M	-$585M
Value	-$1.5B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-	-	-	-	-	-246%	-
ROA	-	-32%	-36%	-42%	-53%	-39%	-58%
ROE	-	-36%	-46%	-55%	-67%	-49%	-76%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-0%
Earnings YoY growth	-	156%	40%	43%	23%	-43%	-
Equity YoY growth	-	-555%	9%	19%	1%	-23%	6%
FCF YoY growth	-	122%	83%	4%	25%	-18%	-